Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.70, $0.04 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.41 billion.

GUIDANCE:

Boston Scientific sees FY2025 EPS of $2.80-$2.87, versus the consensus of $2.81.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.